CNTA
Centessa·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CNTA
Centessa Pharmaceuticals Plc
A clinical-stage pharmaceutical company that developing products to cover a range of high-value indications
Pharmaceutical
10/26/2020
05/28/2021
NASDAQ Stock Exchange
77
12-31
Depository Receipts (Ordinary Shares)
3rd Floor, 1 Ashley Road, Altrincham, Cheshire WA14 2DT, United Kingdom
--
Centessa Pharmaceuticals plc was incorporated in the United Kingdom on October 26, 2020. The company is a clinical-stage pharmaceutical company with a mission to discover, develop and ultimately deliver drugs that are transformative for patients.
Company Financials
EPS
CNTA has released its 2025 Q3 earnings. EPS was reported at -0.41, versus the expected -0.39, missing expectations. The chart below visualizes how CNTA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
